
Pfizer to call off $160 billion merger with Allergan
pharmafile | April 6, 2016 | News story | Business Services, Research and Development, Sales and Marketing |ย ย Allergan, Pfizer, deal, legal, merger and acquisition, regulationย
US pharma giant Pfizer Inc (NYSE: PFE) has decided to terminate the $160 billion merger with Botox-maker Allergan Plc (NYSE: AGN) according to reports, ending the biggest pharma deal as the US lawmakers take to enforcing stricter rules for corporations trying to dodge taxes.
The proposed regulations were announced on Monday by the Treasury Department with the aim to cut transactions that aid inversions for the corporates if there have been other similar deals over the past 36 months. For the same period, Allergan has had several similar acquisitions.
Following the termination, Pficer will be required to pay a $400 million fee to Allergan for expenses relating to the deal.
In November, Ireland-headquarter Allergan agreed to merge with Pfizer in a deal to great the largest healthcare entity in the world. The deal would have also brought down the effective tax rate for Pfizer.
The two companies are likely to make a joint announcement terminating the deal on Wednesday.
Anjali Shukla
Related Content
NICE recommends Pfizerโs new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21stย May 2025ย โย Pfizer Ltd announced today that the National Institute for Health and Care …

Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failureย on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …






